Optimal Sequencing of Anti-HER2 Therapy

[摘要] There is no clear-cut definition of trastuzumab resistance or sensitivity. First, because patients who received trastuzumab in the adjuvant setting also received adjuvant chemotherapy, mostly anthracycline and taxane containing regimens. Second, because probably there is a biological difference between patients with hormone receptor-positive tumors compared to patients with hormone receptor-negative tumors. Therefore, in patients with hormone receptor-negative, HER2-overexpressing tumors probably the definition of trastuzumab resistance is adequate if the patient develops recurrence and/or metastases within 1 year after completion of adjuvant trastuzumab therapy.

[学科分类] 泌尿医学